Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Baxter
Fish and Richardson
UBS
Johnson and Johnson
Colorcon
QuintilesIMS
Cipla
Citi
Harvard Business School

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019680

« Back to Dashboard
NDA 019680 describes DEPAKOTE, which is a drug marketed by Abbvie and Abbott and is included in four NDAs. It is available from four suppliers. There are six patents protecting this drug and two Paragraph IV challenges. Additional details are available on the DEPAKOTE profile page.

The generic ingredient in DEPAKOTE is divalproex sodium. There are seventeen drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the divalproex sodium profile page.

Summary for NDA: 019680

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Anticonvulsants
Antimigraine Agents
Bipolar Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 019680

Suppliers and Packaging for NDA: 019680

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DEPAKOTE
divalproex sodium
CAPSULE, DELAYED REL PELLETS;ORAL 019680 NDA AbbVie Inc. 0074-6114 0074-6114-11 10 BLISTER PACK in 1 CARTON (0074-6114-11) > 10 CAPSULE in 1 BLISTER PACK
DEPAKOTE
divalproex sodium
CAPSULE, DELAYED REL PELLETS;ORAL 019680 NDA AbbVie Inc. 0074-6114 0074-6114-13 100 CAPSULE in 1 BOTTLE (0074-6114-13)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, DELAYED REL PELLETS;ORALStrengthEQ 125MG VALPROIC ACID
Approval Date:Sep 12, 1989TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 019680

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
DEPAKOTE
divalproex sodium
CAPSULE, DELAYED REL PELLETS;ORAL019680-001Sep 12, 1989► Subscribe► Subscribe
Abbvie
DEPAKOTE
divalproex sodium
CAPSULE, DELAYED REL PELLETS;ORAL019680-001Sep 12, 1989► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
UBS
AstraZeneca
Citi
Teva
Mallinckrodt
Daiichi Sankyo
Cantor Fitzgerald
Covington
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot